<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34248855</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1664-2392</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>12</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in endocrinology</Title>
          <ISOAbbreviation>Front Endocrinol (Lausanne)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Challenges in Cytology Specimens With Hürthle Cells.</ArticleTitle>
        <Pagination>
          <StartPage>701877</StartPage>
          <MedlinePgn>701877</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">701877</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fendo.2021.701877</ELocationID>
        <Abstract>
          <AbstractText>In fine-needle aspirations (FNA) of thyroid, Hürthle cells can be found in a broad spectrum of lesions, ranging from non-neoplastic conditions to aggressive malignant tumors. Recognize them morphologically, frequently represents a challenging for an adequately diagnosis and are associated with a significant interobserver variability. Although the limitations of the morphologic diagnosis still exist, the interpretation of the context where the cells appear and the recent advances in the molecular knowledge of Hürthle cells tumors are contributing for a more precise diagnosis. This review aims to describe the cytology aspects of all Hürthle cells neoplastic and non-neoplastic thyroid lesions, focusing on the differential diagnosis and reporting according to The Bethesda System for Reporting Thyroid Cytology (TBSRTC). New entities according to the latest World Health Organization (WHO) classification are included, as well as an update of the current molecular data.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Thodou, Canberk and Schmitt.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Thodou</LastName>
            <ForeName>Eleni</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Medical School, University of Thessaly, Larissa, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Canberk</LastName>
            <ForeName>Sule</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular Pathology and Immunology, University of Porto (Ipatimup), Porto, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schmitt</LastName>
            <ForeName>Fernando</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular Pathology and Immunology, University of Porto (Ipatimup), Porto, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medical Faculty, Porto University, Porto, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>CINTESIS@RISE, Porto, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Endocrinol (Lausanne)</MedlineTA>
        <NlmUniqueID>101555782</NlmUniqueID>
        <ISSNLinking>1664-2392</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D044963" MajorTopicYN="N">Biopsy, Fine-Needle</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003581" MajorTopicYN="N">Cytodiagnosis</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024862" MajorTopicYN="N">Oxyphil Cells</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013961" MajorTopicYN="N">Thyroid Gland</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013964" MajorTopicYN="N">Thyroid Neoplasms</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016606" MajorTopicYN="N">Thyroid Nodule</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Hürthle cell tumors</Keyword>
        <Keyword MajorTopicYN="Y">cytology</Keyword>
        <Keyword MajorTopicYN="Y">neoplasia</Keyword>
        <Keyword MajorTopicYN="Y">oncocytic tumors</Keyword>
        <Keyword MajorTopicYN="Y">thyroid FNA</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>12</Day>
          <Hour>5</Hour>
          <Minute>47</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34248855</ArticleId>
        <ArticleId IdType="pmc">PMC8267832</ArticleId>
        <ArticleId IdType="doi">10.3389/fendo.2021.701877</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Canberk S, LiVolsi VA, Baloch ZW. Oncocytic Lesions of the Neuroendocrine System. Adv Anat Pathol (2014) 21:69–82.  10.1097/PAP.0000000000000011
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAP.0000000000000011</ArticleId>
            <ArticleId IdType="pubmed">24508690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Canberk S, Lima AR, Correia M, Batista R, Soares P, Valdemar Máximo V, et al. . Oncocytic Thyroid Neoplasms: From Histology to Molecular Biology. Diagn Histopathol (2019) 25:154 – 165.  10.1016/j.mpdhp.2019.02.002
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mpdhp.2019.02.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mete O, Asa SL. Oncocytes, Oxyphils, Hürthle, and Askanazy Cells: Morphological and Molecular Features of Oncocytic Thyroid Nodules. Endocr Pathol (2010) 21:16–24.  10.1007/s12022-009-9102-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-009-9102-2</ArticleId>
            <ArticleId IdType="pubmed">20013317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Montone KT, Baloch ZW, LiVolsi VA. The Thyroid Hürthle (Oncocytic) Cell and its Associated Pathologic Conditions: A Surgical Pathology and Cytopathology Review. Arch Pathol Lab Med (2008) 132:1241–50.  10.1043/1543-2165(2008)132[1241:TTHOCA]2.0.CO;2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1043/1543-2165(2008)132[1241:TTHOCA]2.0.CO;2</ArticleId>
            <ArticleId IdType="pubmed">18684023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lloyd RV, Osamura RY, Kloppel G, Rosai J. WHO Classification of Tumours of Endocrine Organs. Lyon: IARC (2017).</Citation>
        </Reference>
        <Reference>
          <Citation>
Xu B, Reznik E, Tuttle RM, Knauf J, Fagin JA, Katabi N, et al. . Outcome and Molecular Characteristics of non-Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma With Oncocytic Features. Endocrine (2019) 64:97–108.  10.1007/s12020-019-01848-6
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-019-01848-6</ArticleId>
            <ArticleId IdType="pmc">PMC6657696</ArticleId>
            <ArticleId IdType="pubmed">30689169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rosario PW, Mourão GF. Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features (NIFTP): A Review for Clinicians. Endocr-Relat Cancer (2019) 26:R259–66.  10.1530/ERC-19-0048
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/ERC-19-0048</ArticleId>
            <ArticleId IdType="pubmed">30913533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schatz-Siemers N, Brandler TC, Oweity T, Sun W, Hernandez A, Levine P. ḦRthle Cell Lesions on Thyroid Fine Needle Aspiration Cytology: Molecular and Histologic Correlation. Diagn Cytopathol (2019) 47:977–85.  10.1002/dc.24247
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dc.24247</ArticleId>
            <ArticleId IdType="pubmed">31293091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jalaly JB, Baloch ZW. Hürthle-Cell Neoplasms of the Thyroid: An Algorithmic Approach to Pathologic Diagnosis in Light of Molecular Advances. Semin Diagn Pathol (2020) 37:234–242.  10.1053/j.semdp.2020.03.004
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.semdp.2020.03.004</ArticleId>
            <ArticleId IdType="pubmed">32444244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wong KS, Trevor EA, Barletta JA, Krane JF. Hürthle Cell Lesions of the Thyroid: Progress Made and Challenges Remaining. Cancer Cytopathol (2021) 129:347–362.  10.1002/cncy.22375. Online ahead of print</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncy.22375.</ArticleId>
            <ArticleId IdType="pubmed">33108684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ali SZ, Cibas ES. The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria and Explanatory Notes. Cham, Switzerland: Springer;  (2018).</Citation>
        </Reference>
        <Reference>
          <Citation>
Yazgan A, Balci S, Dincer N, Kiyak G, Tuzun D, Ersoy R, et al. . Hürthle Cell Presence Alters the Distribution and Outcome of Categories in the Bethesda System for Reporting Thyroid Cytopathology. Cytopathology (2014) 25:185–9.  10.1111/cyt.12093
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cyt.12093</ArticleId>
            <ArticleId IdType="pubmed">24024935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
VandenBussche CJ, Adams C, Ali SZ, Olson MT. Cytotechnologist Performance for Screening Hürthle Cell Atypia in Indeterminate Thyroid Fine-Needle Aspirates. Acta Cytol (2015) 59:377–83.  10.1159/000441939
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000441939</ArticleId>
            <ArticleId IdType="pubmed">26606302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kini SR. Guides to Clinical Aspiration Biopsy. Thyroid (1987). New York: Igaku Shoin.</Citation>
        </Reference>
        <Reference>
          <Citation>
Nguyen GK, Ginsberg J, Crockford PM, Villanueva RR. Hashimoto’s Thyroiditis: Cytodiagnostic Accuracy and Pitfalls. Diagn Cytopathol (1997) 16:531–6.  10.1002/(sici)1097-0339(199706)16:6&lt;531::aid-dc12&gt;3.0.co;2-j
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(sici)1097-0339(199706)16:6&lt;531::aid-dc12&gt;3.0.co;2-j</ArticleId>
            <ArticleId IdType="pubmed">9181321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mac Donald L, Yazdi HM. Fine Needle Aspiration Biopsy of Hashimoto’s Thyroiditis: Sources of Diagnostic Error. Acta Cytol (1999) 43:400–6.  10.1159/000331088
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000331088</ArticleId>
            <ArticleId IdType="pubmed">10349369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Malheiros DC, Canberk S, Poller DN, Schmitt F. Thyroid FNAC: Causes of False-Positive Results. Cytopathology (2018) 29:407–17.  10.1111/cyt.12575
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cyt.12575</ArticleId>
            <ArticleId IdType="pubmed">29768677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yi K-I, Ahn S, Park DY, Lee J-C, Lee B-J, Wang S-G, et al. . False-positive Cytopathology Results for Papillary Thyroid Carcinoma: A Trap for Thyroid Surgeons. Clin Otolaryngol (2017) 42:1153–60.  10.1111/coa.12840
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/coa.12840</ArticleId>
            <ArticleId IdType="pubmed">28130940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Canberk S, Firat P, Schmitt F. Pitfalls in the Cytological Assessment of Thyroid Nodules. Turk Patoloji Derg (2015) 31:18–33.  10.5146/tjpath.2015.01312
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5146/tjpath.2015.01312</ArticleId>
            <ArticleId IdType="pubmed">26177315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Harvey AM, Truong LD, Mody DR. Diagnostic Pitfalls of Hashimoto’s/Lymphocytic Thyroiditis on Fine-Needle Aspirations and Strategies to Avoid Overdiagnosis. Acta Cytol (2012) 56:352–60.  10.1159/000338738
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000338738</ArticleId>
            <ArticleId IdType="pubmed">22846513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ravinsky E, Safneck JR. Differentiation of Hashimoto’s Thyroiditis From Thyroid Neoplasms in Fine Needle Aspirates. Acta Cytol (1988) 32:854–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3201876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Elliott DD, Pitman MB, Bloom L, Faquin WC. FNA Biopsy of Hürthle Cell Lesions of the Thyroid Gland: A Cytomorphologic Study of 139 Cases With Statistical Analysis. Cancer (2006) 108:102–9.  10.1002/cncr.21716
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.21716</ArticleId>
            <ArticleId IdType="pubmed">16453320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kasper KA, Stewart J, Das K. Fine-Needle Aspiration Cytology of Thyroid Nodules With Hürthle Cells: Cytomorphologic Predictors for Neoplasms, Improving Diagnostic Accuracy and Overcoming Pitfalls. Acta Cytol (2014) 58:145–52.  10.1159/000358264
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000358264</ArticleId>
            <ArticleId IdType="pubmed">24525356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Alaedeen DI, Khiyami A, McHenry CR. Fine-Needle Aspiration Biopsy Specimen With a Predominance of Hürthle Cells: A Dilemma in the Management of Nodular Thyroid Disease. Surgery (2005) 138:650–7.  10.1016/j.surg.2005.06.047
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.surg.2005.06.047</ArticleId>
            <ArticleId IdType="pubmed">16269293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Auger M. Hürthle Cells in Fine-Needle Aspirates of the Thyroid. A Review of Their Diagnostic Criteria and Significance. Cancer Cytopathol (2014) 122:241–9.  10.1002/cncy.21391
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncy.21391</ArticleId>
            <ArticleId IdType="pubmed">24436122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Faquin WC, Cibas ES, Renshaw A. “Atypical” Cells in Fine-Needle Aspiration Biopsy Specimens of Benign Thyroid Cysts. Cancer (2005) 105:71–9.  10.1002/cncr.20832
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.20832</ArticleId>
            <ArticleId IdType="pubmed">15662703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yang GCH, Schreiner AM, Sun W. Can Abundant Colloid Exclude Oncocytic (Hürthle Cell) Carcinoma in Thyroid fine Needle Aspiration? Cytohistological Correlation of 127 Oncocytic (Hürthle Cell) Lesions. Cytopathology (2013) 24:185–93.  10.1111/j.1365-2303.2012.00988.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2303.2012.00988.x</ArticleId>
            <ArticleId IdType="pubmed">22672530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Renshaw A. Hürthle Cell Carcinoma is a Better Gold Standard Than Hürthle Cell Neoplasm for Fine-Needle Aspiration of the Thyroid: Defining More Consistent and Specific Cytologic Criteria. Cancer Cytopathol (2002) 96:261–6.  10.1002/cncr.10797
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.10797</ArticleId>
            <ArticleId IdType="pubmed">12378592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kini SR, Miller JM, Hamburger JI. Cytopathology of Hürthle Cell Lesions of the Thyroid Gland by fine Needle Aspiration. Acta Cytol (1981) 25:647–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6171979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yang YJ, Khurana KK. Diagnostic Utility of Intracytoplasmic Lumen and Transgressing Vessels in Evaluation of Hürthle Cell Lesions by Fine-Needle Aspiration. Arch Pathol Lab Med (2001) 125:1031–5.  10.1043/0003-9985(2001)125&lt;1031:DUOILA&gt;2.0.CO;2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1043/0003-9985(2001)125&lt;1031:DUOILA&gt;2.0.CO;2</ArticleId>
            <ArticleId IdType="pubmed">11473452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wu HH-J, Clouse J, Ren R. Fine-Needle Aspiration Cytology of Hürthle Cell Carcinoma of the Thyroid. Diagn Cytopathol (2008) 36:149–54.  10.1002/dc.2075067
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dc.2075067</ArticleId>
            <ArticleId IdType="pubmed">18232004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mu N, Juhlin CC, Tani E, Sofiadis A, Reihnér E, Zedenius J, et al. . High Ki-67 Index in Fine Needle Aspiration Cytology of Follicular Thyroid Tumors is Associated With Increased Risk of Carcinoma. Endocrine (2018) 61:293–302.  10.1007/s12020-018-1627-z
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-018-1627-z</ArticleId>
            <ArticleId IdType="pmc">PMC6061212</ArticleId>
            <ArticleId IdType="pubmed">29796987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Canberk S, Montezuma D, Ince U, Tastekin E, Soares P, Bongiovanni M, et al. . Variants of Papillary Thyroid Carcinoma: An Algorithmic Cytomorphology-Based Approach to Cytology Specimens. Acta Cytol (2020) 64:288–98.  10.1159/000503576
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000503576</ArticleId>
            <ArticleId IdType="pubmed">31634886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baloch Z, LiVolsi VA, Tondon R. Aggressive Variants of Follicular Cell Derived Thyroid Carcinoma; the So Called “Real Thyroid Carcinomas”. J Clin Pathol (2013) 66:733–43. 10.1136/jclinpath-2013-201626
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jclinpath-2013-201626</ArticleId>
            <ArticleId IdType="pubmed">23626010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Silver CE, Owen RP, Rodrigo JP, Rinaldo A, Devaney KO, Ferlito A. Aggressive Variants of Papillary Thyroid Carcinoma. Head Neck (2011) 33:1052–9. 10.1002/hed.21494
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hed.21494</ArticleId>
            <ArticleId IdType="pubmed">20824810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Asioli S, Maletta F, Pagni F, Pacchioni D, Vanzati A, Mariani S, et al. . Cytomorphologic and Molecular Features of Hobnail Variant of Papillary Thyroid Carcinoma: Case Series and Literature Review. Diagn Cytopathol (2014) 42:78–84.  10.1002/dc.23028
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dc.23028</ArticleId>
            <ArticleId IdType="pubmed">23913779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bellevicine C, Cozzolino I, Malapelle U, Zeppa P, Troncone G. Cytological and Molecular Features of Papillary Thyroid Carcinoma With Prominent Hobnail Features: A Case Report. Acta Cytol. (2012) 56(5):560–4. 10.1159/000338395
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000338395</ArticleId>
            <ArticleId IdType="pubmed">23075900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wenter V, Jellinek A, Unterrainer M, Ahmaddy F, Lehner S, Albert NL, et al. . Long-Term Outcome of Rare Oncocytic Papillary (Hürthle Cell) Thyroid Carcinoma Following (Adjuvant) Initial Radioiodine Therapy. Eur J Nucl Med Mol Imaging (2019) 46:2526–35.  10.1007/s00259-019-04456-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00259-019-04456-8</ArticleId>
            <ArticleId IdType="pubmed">31410542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Carr AA, Yen TWF, Ortiz DI, Hunt BC, Fareau G, Massey BL, et al. . Patients With Oncocytic Variant Papillary Thyroid Carcinoma Have a Similar Prognosis to Matched Classical Papillary Thyroid Carcinoma Controls. Thyroid (2018) 28:1462–7.  10.1089/thy.2017.0603
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2017.0603</ArticleId>
            <ArticleId IdType="pubmed">30215297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baloch ZW, LiVolsi VA. Warthin-Like Papillary Carcinoma of the Thyroid. Arch Pathol Lab Med (2000) 124:1192–5.  10.1043/0003-9985(2000)124&lt;1192:WLPCOT&gt;2.0.CO;2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1043/0003-9985(2000)124&lt;1192:WLPCOT&gt;2.0.CO;2</ArticleId>
            <ArticleId IdType="pubmed">10923082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lastra RR, LiVolsi VA, Baloch ZW. Aggressive Variants of Follicular Cell-Derived Thyroid Carcinomas: A Cytopathologist’s Perspective. Cancer. Cytopathol (2014) 122:484–503.  10.1002/cncy.21417
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncy.21417</ArticleId>
            <ArticleId IdType="pubmed">24664970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Solomon A, Gupta PK, LiVolsi VA, Baloch ZW. Distinguishing Tall Cell Variant of Papillary Thyroid Carcinoma From Usual Variant of Papillary Thyroid Carcinoma in Cytologic Specimens. Diagn Cytopathol (2002) 27:143–8. 10.1002/dc.10156
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dc.10156</ArticleId>
            <ArticleId IdType="pubmed">12203860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Das DK, Mallik MK, Sharma P, Sheikh ZA, Mathew PA, Sheikh M, et al. . Papillary Thyroid Carcinoma and its Variants in Fine Needle Aspiration Smears. A Cytomorphologic Study With Special Reference to Tall Cell Variant. Acta Cytol (2004) 48:325–36.  10.1159/000326381
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000326381</ArticleId>
            <ArticleId IdType="pubmed">15192947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW. Does Hurthle Cell Lesion/Neoplasm Predict Malignancy More Than Follicular Lesion/Neoplasm on Thyroid Fine-Needle Aspiration? Diagn Cytopathol (2006) 34:330–4.  10.1002/dc.20440
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dc.20440</ArticleId>
            <ArticleId IdType="pubmed">16604553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Giorgadze T, Rossi ED, Fadda G, Gupta PK, Livolsi VA, Baloch Z. Does the Fine-Needle Aspiration Diagnosis of “Hürthle-Cell Neoplasm/Follicular Neoplasm With Oncocytic Features” Denote Increased Risk of Malignancy? Diagn Cytopathol (2004) 31:307–12.  10.1002/dc.20132
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dc.20132</ArticleId>
            <ArticleId IdType="pubmed">15468114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Roh MH, Jo VY, Stelow EB, Faquin WC, Zou KH, Alexander EK, et al. . The Predictive Value of the Fine-Needle Aspiration Diagnosis “Suspicious for a Follicular Neoplasm, Hurthle Cell Type” in Patients With Hashimoto Thyroiditis. Am J Clin Pathol (2011) 135:139–45.  10.1309/AJCP0RW2WMDUAKGK
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1309/AJCP0RW2WMDUAKGK</ArticleId>
            <ArticleId IdType="pubmed">21173136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mai KT, Elmontaser G, Perkins DG, Thomas J, Stinson WA. Benign Hürthle Cell Adenoma With Papillary Architecture: A Benign Lesion Mimicking Oncocytic Papillary Carcinoma. Int J Surg Pathol (2005) 13:37– 41.  10.1177/106689690501300105
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/106689690501300105</ArticleId>
            <ArticleId IdType="pubmed">15735853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Woodford RL, Nikiforov YE, Hunt JL, Bellizzi AM, Zhang X. Mills SE, et al. Encapsulated Papillary Oncocytic Neoplasms of the Thyroid: Morphologic, Immunohistochemical, and Molecular Analysis of 18 Cases. Am J Surg Pathol (2010) 34:1582–90.  10.1097/PAS.0b013e3181f2d820
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAS.0b013e3181f2d820</ArticleId>
            <ArticleId IdType="pubmed">20924280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bellevicine C, Malapelle U, Docimo G, Ciancia G, Mossetti G, Pettinato G, et al. . Multicentric Encapsulated Papillary Oncocytic Neoplasm of the Thyroid: A Case Diagnosed by a Combined Cytological, Histological, Immunohistochemical, and Molecular Approach. Diagn Cytopathol (2012) 40:450–4.  10.1002/dc.21828
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dc.21828</ArticleId>
            <ArticleId IdType="pubmed">21965084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Apel RL, Asa SL, LiVolsi VA. Papillary Hürthle Cell Carcinoma With Lymphocytic Stroma. “Warthin-Like Tumor” of the Thyroid. Am J Surg Pathol (1995) 19:810–4. 10.1097/00000478-199507000-00009
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00000478-199507000-00009</ArticleId>
            <ArticleId IdType="pubmed">7793479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim J, Lim BJ, Hong SW, Pyo JY. Preoperative Cytologic Diagnosis of Warthin-Like Variant of Papillary Thyroid Carcinoma. J Pathol Transl Med (2018) 52:105–9.  10.4132/jptm.2017.12.26
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4132/jptm.2017.12.26</ArticleId>
            <ArticleId IdType="pmc">PMC5859244</ArticleId>
            <ArticleId IdType="pubmed">29429327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dettmer M, Schmitt A, Steinert H, Moch H, Komminoth P, Perren A. Poorly Differentiated Oncocytic Thyroid Carcinoma—Diagnostic Implications and Outcome. Histopathology (2012) 60:1045–51.  10.1111/j.1365-2559.2012.04188.x53
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2559.2012.04188.x53</ArticleId>
            <ArticleId IdType="pubmed">22348590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Asioli S, Erickson LA, Righi A, Jin L, Volante M, Jenkins S, et al. . Poorly Differentiated Carcinoma of the Thyroid: Validation of the Turin Proposal and Analysis of IMP3 Expression. Mod Pathol (2010) 23:1269–78.  10.1038/modpathol.2010.117
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/modpathol.2010.117</ArticleId>
            <ArticleId IdType="pubmed">20562850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wong KS, Lorch JH, Alexander EK, Marqusee E, Cho NL, Nehs MA, et al. . Prognostic Significance of Extent of Invasion in Poorly Differentiated Thyroid Carcinoma. Thyroid (2019) 29:1255–61.  10.1089/thy.2019.0263
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2019.0263</ArticleId>
            <ArticleId IdType="pubmed">31397224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bongiovanni M, Bloom L, Krane JF, Baloch ZW, Powers CN, Hintermann S, et al. . Cytomorphologic Features of Poorly Differentiated Thyroid Carcinoma: A Multi-Institutional Analysis of 40 Cases. Cancer Cytopathol (2009) 117:185–94.  10.1002/cncy.20023
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncy.20023</ArticleId>
            <ArticleId IdType="pubmed">19365842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kane SV, Sharma TP. Cytologic Diagnostic Approach to Poorly Differentiated Thyroid Carcinoma: A Single-Institution Study. Cancer Cytopathol (2015) 123:82–91.  10.1002/cncy.21500
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncy.21500</ArticleId>
            <ArticleId IdType="pubmed">25557073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Onenerk M, Canberk S, Gunes P, Erkan M, Kilicoglu GZ. Oncocytic Variant of Poorly Differentiated Thyroid Carcinoma: “Is Diagnosis Possible by Fine-Needle Aspiration?”
Cytojournal (2016) 13:23.  10.4103/1742-6413.192188
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/1742-6413.192188</ArticleId>
            <ArticleId IdType="pmc">PMC5070041</ArticleId>
            <ArticleId IdType="pubmed">27761148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Laforga JB, Cortés VA. Oncocytic Poorly Differentiated (Insular) Thyroid Carcinoma Mimicking Metastatic Adenocarcinoma. A Case Report and Review of the Literature. Diagn Cytopathol (2019) 47:584–8.  10.1002/dc.24147
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dc.24147</ArticleId>
            <ArticleId IdType="pubmed">30637975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Papaparaskeva K, Nagel H, Droese M. Cytologic Diagnosis of Medullary Carcinoma of the Thyroid Gland. Diagn Cytopathol (2000) 22:351–8.  10.1002/(sici)1097-0339(200006)22:6&lt;351::aid-dc5&gt;3.0.co;2-t
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(sici)1097-0339(200006)22:6&lt;351::aid-dc5&gt;3.0.co;2-t</ArticleId>
            <ArticleId IdType="pubmed">10820528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Trimboli P, Treglia G, Guidobaldi L, Romanelli F, Nigri G, Valabrega S, et al. . Detection Rate of FNA Cytology in Medullary Thyroid Carcinoma: A Meta-Analysis. Clin Endocrinol (2015) 82:280–5.  10.1111/cen.12563
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cen.12563</ArticleId>
            <ArticleId IdType="pubmed">25047365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Canberk S, Onenerk M, Gunes P, Sayman E, Kilicoglu G. Oncocytic Variant of Medullary Thyroid Carcinoma. Endocr Pathol (2015) 26:320–3.  10.1007/s12022-015-9389-0
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-015-9389-0</ArticleId>
            <ArticleId IdType="pubmed">26293669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Spaulding SL, Ho R, Everest S, Chai RL. The Role of Molecular Testing in the Diagnosis of Medullary Thyroid Cancer: A Case Report of Oncocytic Medullary Thyroid Carcinoma and Review of the Literature. Am J Otolaryngol (2020) 41:102312.  10.1016/j.amjoto.2019.102312
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amjoto.2019.102312</ArticleId>
            <ArticleId IdType="pubmed">31727331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dedivitis RA, Di Giovanni JH, Silva GF, Marinho LC, Guimarães AV. Oncocytic Variant Ofmedullary Thyroid Carcinoma: Case Report. Arq Bras Endocrinol Metabol (2004) 48:315–7.  10.1590/s0004-27302004000200017
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1590/s0004-27302004000200017</ArticleId>
            <ArticleId IdType="pubmed">15640889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kaushal S, Iyer VK, Mathur SR, Ray R. Fine Needle Aspiration Cytology of Medullary Carcinoma of the Thyroid With a Focus on Rare Variants: A Review of 78 Cases. Cytopathology (2011) 22:95–105.  10.1111/j.1365-2303.2010.00747.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2303.2010.00747.x</ArticleId>
            <ArticleId IdType="pubmed">20518799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sams SB, Tompkins KD, Mayson S, Raeburn CD, Mehrotra S. Oncocytic Variant of Medullary Thyroid Carcinoma; A Rare Tumor With Numerous Diagnostic Mimics by Fine Needle Aspiration. Diagn Cytopathol (2017) 45:1148–52.  10.1002/dc.23790
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dc.23790</ArticleId>
            <ArticleId IdType="pubmed">28802094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maximo V, Sobrinho-Simoes M. Hürthle Cell Tumours of the Thyroid. A Review With Emphasis on Mitochondrial Abnormalities With Clinical Relevance. Virchows Arch (2000) 437:107–15.  10.1007/s004280000219
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004280000219</ArticleId>
            <ArticleId IdType="pubmed">10993269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maximo V, Sobrinho-Simoes M. Mitochondrial DNA ‘Common’ Deletion in Hürthle Cell Lesions of the Thyroid. J Pathol (2000) 192:561–2.  10.1002/1096-9896(200012)192:4&lt;561::AID-PATH790&gt;3.0.CO;2-3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1096-9896(200012)192:4&lt;561::AID-PATH790&gt;3.0.CO;2-3</ArticleId>
            <ArticleId IdType="pubmed">11113879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ganly I, McFadden DG. Short Review: Genomic Alterations in Hürthle Cell Carcinoma. Thyroid (2019) 29:471–9.  10.1089/thy.2019.0088
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2019.0088</ArticleId>
            <ArticleId IdType="pubmed">30848171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ganly I, Makarov V, Deraje S, Dong Y, Reznik E, Seshan V, et al. . Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell (2018) 34:256–70.  10.1016/j.ccell.2018.07.002
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2018.07.002</ArticleId>
            <ArticleId IdType="pmc">PMC6247912</ArticleId>
            <ArticleId IdType="pubmed">30107176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, et al. . RAS Point Mutations and PAX8-PPAR Gamma Rearrangement in Thyroid Tumors: Evidence for Distinct Molecular Pathways in Thyroid Follicular Carcinoma. J Clin Endocrinol Metab (2003) 88:2318–26.  10.1210/jc.2002-021907
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2002-021907</ArticleId>
            <ArticleId IdType="pubmed">12727991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, et al. . TERT Promoter Mutations are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas. J Clin Endocrinol Metab (2014) 99:E754–765.  10.1210/jc.2013-3734
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2013-3734</ArticleId>
            <ArticleId IdType="pmc">PMC4191548</ArticleId>
            <ArticleId IdType="pubmed">24476079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chindris AM, Casler JD, Bernet VJ, Rivera M, Thomas C, Kachergus JM, et al. . Clinical and Molecular Features of Hürthle Cell Carcinoma of the Thyroid. J ClinEndocrinol Metab (2015) 100:55–62.  10.1210/jc.2014-1634
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2014-1634</ArticleId>
            <ArticleId IdType="pubmed">25259908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vinagre J, Almeida A, Pópulo H, Batista R, Lyra J, Pinto V, et al. . Frequency of TERT Pro- Moter Mutations in Human Cancers. Nat Commun (2013) 4:2185.  10.1038/ncomms3185
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms3185</ArticleId>
            <ArticleId IdType="pubmed">23887589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, et al. . Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease. J Clin Endocrinol Metab (2013) 98:E1562–1566.  10.1210/jc.2013-2383
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2013-2383</ArticleId>
            <ArticleId IdType="pmc">PMC3763971</ArticleId>
            <ArticleId IdType="pubmed">23833040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
de Vries MM, Celestino R, Castro P, Eloy C, Máximo V, Van Der Wal JE, et al. . RET/PTC Rearrangement is Prevalent in Follicular Hürthle Cell Carcinomas. Histopathology (2012) 61:833–43.  10.1111/j.1365-2559.2012.04276.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2559.2012.04276.x</ArticleId>
            <ArticleId IdType="pubmed">22803838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cheung CC, Ezzat S, Ramyar L, Freeman JL, Asa SL. Molecular Basis Off Hürthle Cell Papillary Thyroid Carcinoma. J Clin Endocrinol Metab (2000) 85:878–82.  10.1210/jcem.85.2.6404
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jcem.85.2.6404</ArticleId>
            <ArticleId IdType="pubmed">10690905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chiappetta G, Toti P, Cetta F, Giuliano A, Pentimalli F, Amendola I, et al. . The RET/PTC Oncogene is Frequently Activated in Oncocytic Thyroid Tumors (Hürthle Cell Adenomas and Carcinomas), But Not in Oncocytic Hyperplastic Lesions. J Clin Endocrinol Metab (2002) 87:364–49.  10.1210/jcem.87.1.8180
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jcem.87.1.8180</ArticleId>
            <ArticleId IdType="pubmed">11788677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gopal RK, Kübler K, Calvo SE, Polak P, Livitz D, Rosebrocket D, et al. . Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma. Cancer Cell (2018) 34:242–355.  10.1016/j.ccell.2018.06.013
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2018.06.013</ArticleId>
            <ArticleId IdType="pmc">PMC6121811</ArticleId>
            <ArticleId IdType="pubmed">30107175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ganly I, Ricarte Filho J, Eng S, Ghossein R, Morris LG, Liang Y, et al. . Genomic Dissection of Hürthle Cell Carcinoma Reveals a Unique Class of Thyroid Malignancy. J Clin Endocrinol Metab (2013) 98:E962–972.  10.1210/jc.2012-3539
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2012-3539</ArticleId>
            <ArticleId IdType="pmc">PMC5393465</ArticleId>
            <ArticleId IdType="pubmed">23543667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Corver WE, Ruano D, Weijers K, den Hartog WC, van Nieuwenhuizen MP, de Miranda N, et al. . Genome Haploidisation With Chromosome 7 Retention in Oncocytic Follicular Thyroid Carcinoma. PloS One (2012) . 7:e38287.  10.1371/journal.pone.0038287
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0038287</ArticleId>
            <ArticleId IdType="pmc">PMC3365880</ArticleId>
            <ArticleId IdType="pubmed">22675538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Corver WE, van Wezel T, Molenaar K, Schrumpf M, van den Akker B, van Eijk R, et al. . Near-haploidization Significantly Associates With Oncocytic Adrenocortical, Thyroid, and Parathyroid Tumors But Not With Mitochondrial DNA Mutations. Genes Chromosomes Cancer (2014) 53:833–44.  10.1002/gcc.22194
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/gcc.22194</ArticleId>
            <ArticleId IdType="pubmed">24909752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA Expression Profiling of Thyroid Tumors: Biological Significance and Diagnostic Utility. J Clin Endocrinol Metab (2008) 93:1600–8. 10.1210/jc.2007-2696
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2007-2696</ArticleId>
            <ArticleId IdType="pmc">PMC2386678</ArticleId>
            <ArticleId IdType="pubmed">18270258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brauner E, Holmes BJ, Krane JF, Nishino M, Zurakowski D, Hennessey JV, et al. . Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs From Other Indeterminate Thyroid Nodules. Thyroid (2015) 25:789–96.  10.1089/thy.2015.0049
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2015.0049</ArticleId>
            <ArticleId IdType="pubmed">25962906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lastra RR, Pramick MR, Crammer CJ, LiVolsi VA, Baloch ZW. Implications of a Suspicious Afirma Test Result in Thyroid Fine-Needle Aspiration Cytology: An Institutional Experience. Cancer Cytopathol (2014) 122:737–44.  10.1002/cncy.21455
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncy.21455</ArticleId>
            <ArticleId IdType="pubmed">25123499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yang SE, Sullivan PS, Zhang J, Govind R, Levin MR, Rao JY, et al. . Has Afirma Gene Expression Classifier Testing Refined the Indeterminate Thyroid Category in Cytology? Cancer Cytopathol (2016) 124:100–9.  10.1002/cncy.21624
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncy.21624</ArticleId>
            <ArticleId IdType="pubmed">26422098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
McIver B, Castro MR, Morris JC, Bernet V, Smallridge R, Henry M, et al. . An Independent Study of a Gene Expression Classifier (Afirma) in the Evaluation of Cytologically Indeterminate Thyroid Nodules. J Clin Endocrinol Metab (2014) 99:4069–77.  10.1210/jc.2013-3584
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2013-3584</ArticleId>
            <ArticleId IdType="pubmed">24780044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, et al. . Preoperative Diagnosis of Benign Thyroid Nodules With Indeterminate Cytology. N Engl J Med (2012) 367:705–15.  10.1056/NEJMoa1203208
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1203208</ArticleId>
            <ArticleId IdType="pubmed">22731672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Harrell RM, Bimston DN. Surgical Utility of Afirma: Effects of High Cancer Prevalence and Oncocytic Cell Types in Patients With Indeterminate Thyroid Cytology. Endocr Pract (2014) 20:364–9.  10.4158/EP13330.OR
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4158/EP13330.OR</ArticleId>
            <ArticleId IdType="pubmed">24246351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wu JX, Young S, Hung ML, Li N, Yang SE, Cheung DS, et al. . Clinical Factors Influencing the Performance of Gene Expression Classifier Testing in Indeterminate Thyroid Nodules. Thyroid (2016) 26:916–22.  10.1089/thy.2015.0505
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2015.0505</ArticleId>
            <ArticleId IdType="pubmed">27161519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Patel KN, Angell TE, Babiarz J, Barth NM, Blevins T, Duh QY, et al. . Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules. JAMA Surg (2018) 153:817–24.  10.1001/jamasurg.2018.1153
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamasurg.2018.1153</ArticleId>
            <ArticleId IdType="pmc">PMC6583881</ArticleId>
            <ArticleId IdType="pubmed">29799911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
San Martin VT, Lawrence L, Bena J, Madhun NZ,  Berber E, Elsheikh TM, et al. . Real-World Comparison of Afirma GEC and GSC for the Assessment of Cytologically Indeterminate Thyroid Nodules. J Clin Endocrinol Metab (2020) 105:428–35.  10.1210/clinem/dgz099
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/clinem/dgz099</ArticleId>
            <ArticleId IdType="pubmed">31665322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pearlstein S, Lahouti AH, Opher E, Nikiforov YE, Kuriloff DB. Thyroseq V3 Molecular Profiling for Tailoring the Surgical Management of Hürthle Cell Neoplasms. Case Rep Endocrinol (2018) 2018:9329035.  10.1155/2018/9329035
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2018/9329035</ArticleId>
            <ArticleId IdType="pmc">PMC6076910</ArticleId>
            <ArticleId IdType="pubmed">30105107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ahmadi S, Stang M, Jiang XS, Sosa JA. ḦRthle Cell Carcinoma: Current Perspectives. Onco Targets Ther (2016) 9:6873–84.  10.2147/OTT.S119980
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S119980</ArticleId>
            <ArticleId IdType="pmc">PMC5106236</ArticleId>
            <ArticleId IdType="pubmed">27853381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hassan A, Khalid M, Riaz S, Nawaz MK, Bashir H. Follicular Thyroid Carcinoma: Disease Response Evaluation Using American Thyroid Association Risk Assessment Guidelines. Eur Thyroid J (2015) 4:260–65.  10.1159/000442237
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000442237</ArticleId>
            <ArticleId IdType="pmc">PMC4716413</ArticleId>
            <ArticleId IdType="pubmed">26835430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
National Comprehensive Cancer Network . Thyroid Cancer (Version 1.2018) . Available at: https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf (Accessed November 8, 2018).</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34248855</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1664-2392</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>12</Volume>
            <PubDate>
              <Year>2021</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in endocrinology</Title>
          <ISOAbbreviation>Front Endocrinol (Lausanne)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Challenges in Cytology Specimens With Hürthle Cells.</ArticleTitle>
        <Pagination>
          <StartPage>701877</StartPage>
          <MedlinePgn>701877</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">701877</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fendo.2021.701877</ELocationID>
        <Abstract>
          <AbstractText>In fine-needle aspirations (FNA) of thyroid, Hürthle cells can be found in a broad spectrum of lesions, ranging from non-neoplastic conditions to aggressive malignant tumors. Recognize them morphologically, frequently represents a challenging for an adequately diagnosis and are associated with a significant interobserver variability. Although the limitations of the morphologic diagnosis still exist, the interpretation of the context where the cells appear and the recent advances in the molecular knowledge of Hürthle cells tumors are contributing for a more precise diagnosis. This review aims to describe the cytology aspects of all Hürthle cells neoplastic and non-neoplastic thyroid lesions, focusing on the differential diagnosis and reporting according to The Bethesda System for Reporting Thyroid Cytology (TBSRTC). New entities according to the latest World Health Organization (WHO) classification are included, as well as an update of the current molecular data.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Thodou, Canberk and Schmitt.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Thodou</LastName>
            <ForeName>Eleni</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Medical School, University of Thessaly, Larissa, Greece.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Canberk</LastName>
            <ForeName>Sule</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Porto, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular Pathology and Immunology, University of Porto (Ipatimup), Porto, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schmitt</LastName>
            <ForeName>Fernando</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular Pathology and Immunology, University of Porto (Ipatimup), Porto, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Medical Faculty, Porto University, Porto, Portugal.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>CINTESIS@RISE, Porto, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Endocrinol (Lausanne)</MedlineTA>
        <NlmUniqueID>101555782</NlmUniqueID>
        <ISSNLinking>1664-2392</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D044963" MajorTopicYN="N">Biopsy, Fine-Needle</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003581" MajorTopicYN="N">Cytodiagnosis</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024862" MajorTopicYN="N">Oxyphil Cells</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013961" MajorTopicYN="N">Thyroid Gland</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013964" MajorTopicYN="N">Thyroid Neoplasms</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016606" MajorTopicYN="N">Thyroid Nodule</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Hürthle cell tumors</Keyword>
        <Keyword MajorTopicYN="Y">cytology</Keyword>
        <Keyword MajorTopicYN="Y">neoplasia</Keyword>
        <Keyword MajorTopicYN="Y">oncocytic tumors</Keyword>
        <Keyword MajorTopicYN="Y">thyroid FNA</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>12</Day>
          <Hour>5</Hour>
          <Minute>47</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34248855</ArticleId>
        <ArticleId IdType="pmc">PMC8267832</ArticleId>
        <ArticleId IdType="doi">10.3389/fendo.2021.701877</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Canberk S, LiVolsi VA, Baloch ZW. Oncocytic Lesions of the Neuroendocrine System. Adv Anat Pathol (2014) 21:69–82.  10.1097/PAP.0000000000000011
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAP.0000000000000011</ArticleId>
            <ArticleId IdType="pubmed">24508690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Canberk S, Lima AR, Correia M, Batista R, Soares P, Valdemar Máximo V, et al. . Oncocytic Thyroid Neoplasms: From Histology to Molecular Biology. Diagn Histopathol (2019) 25:154 – 165.  10.1016/j.mpdhp.2019.02.002
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.mpdhp.2019.02.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mete O, Asa SL. Oncocytes, Oxyphils, Hürthle, and Askanazy Cells: Morphological and Molecular Features of Oncocytic Thyroid Nodules. Endocr Pathol (2010) 21:16–24.  10.1007/s12022-009-9102-2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-009-9102-2</ArticleId>
            <ArticleId IdType="pubmed">20013317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Montone KT, Baloch ZW, LiVolsi VA. The Thyroid Hürthle (Oncocytic) Cell and its Associated Pathologic Conditions: A Surgical Pathology and Cytopathology Review. Arch Pathol Lab Med (2008) 132:1241–50.  10.1043/1543-2165(2008)132[1241:TTHOCA]2.0.CO;2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1043/1543-2165(2008)132[1241:TTHOCA]2.0.CO;2</ArticleId>
            <ArticleId IdType="pubmed">18684023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lloyd RV, Osamura RY, Kloppel G, Rosai J. WHO Classification of Tumours of Endocrine Organs. Lyon: IARC (2017).</Citation>
        </Reference>
        <Reference>
          <Citation>
Xu B, Reznik E, Tuttle RM, Knauf J, Fagin JA, Katabi N, et al. . Outcome and Molecular Characteristics of non-Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma With Oncocytic Features. Endocrine (2019) 64:97–108.  10.1007/s12020-019-01848-6
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-019-01848-6</ArticleId>
            <ArticleId IdType="pmc">PMC6657696</ArticleId>
            <ArticleId IdType="pubmed">30689169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rosario PW, Mourão GF. Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features (NIFTP): A Review for Clinicians. Endocr-Relat Cancer (2019) 26:R259–66.  10.1530/ERC-19-0048
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/ERC-19-0048</ArticleId>
            <ArticleId IdType="pubmed">30913533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schatz-Siemers N, Brandler TC, Oweity T, Sun W, Hernandez A, Levine P. ḦRthle Cell Lesions on Thyroid Fine Needle Aspiration Cytology: Molecular and Histologic Correlation. Diagn Cytopathol (2019) 47:977–85.  10.1002/dc.24247
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dc.24247</ArticleId>
            <ArticleId IdType="pubmed">31293091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Jalaly JB, Baloch ZW. Hürthle-Cell Neoplasms of the Thyroid: An Algorithmic Approach to Pathologic Diagnosis in Light of Molecular Advances. Semin Diagn Pathol (2020) 37:234–242.  10.1053/j.semdp.2020.03.004
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.semdp.2020.03.004</ArticleId>
            <ArticleId IdType="pubmed">32444244</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wong KS, Trevor EA, Barletta JA, Krane JF. Hürthle Cell Lesions of the Thyroid: Progress Made and Challenges Remaining. Cancer Cytopathol (2021) 129:347–362.  10.1002/cncy.22375. Online ahead of print</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncy.22375.</ArticleId>
            <ArticleId IdType="pubmed">33108684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ali SZ, Cibas ES. The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria and Explanatory Notes. Cham, Switzerland: Springer;  (2018).</Citation>
        </Reference>
        <Reference>
          <Citation>
Yazgan A, Balci S, Dincer N, Kiyak G, Tuzun D, Ersoy R, et al. . Hürthle Cell Presence Alters the Distribution and Outcome of Categories in the Bethesda System for Reporting Thyroid Cytopathology. Cytopathology (2014) 25:185–9.  10.1111/cyt.12093
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cyt.12093</ArticleId>
            <ArticleId IdType="pubmed">24024935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
VandenBussche CJ, Adams C, Ali SZ, Olson MT. Cytotechnologist Performance for Screening Hürthle Cell Atypia in Indeterminate Thyroid Fine-Needle Aspirates. Acta Cytol (2015) 59:377–83.  10.1159/000441939
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000441939</ArticleId>
            <ArticleId IdType="pubmed">26606302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kini SR. Guides to Clinical Aspiration Biopsy. Thyroid (1987). New York: Igaku Shoin.</Citation>
        </Reference>
        <Reference>
          <Citation>
Nguyen GK, Ginsberg J, Crockford PM, Villanueva RR. Hashimoto’s Thyroiditis: Cytodiagnostic Accuracy and Pitfalls. Diagn Cytopathol (1997) 16:531–6.  10.1002/(sici)1097-0339(199706)16:6&lt;531::aid-dc12&gt;3.0.co;2-j
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(sici)1097-0339(199706)16:6&lt;531::aid-dc12&gt;3.0.co;2-j</ArticleId>
            <ArticleId IdType="pubmed">9181321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mac Donald L, Yazdi HM. Fine Needle Aspiration Biopsy of Hashimoto’s Thyroiditis: Sources of Diagnostic Error. Acta Cytol (1999) 43:400–6.  10.1159/000331088
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000331088</ArticleId>
            <ArticleId IdType="pubmed">10349369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Malheiros DC, Canberk S, Poller DN, Schmitt F. Thyroid FNAC: Causes of False-Positive Results. Cytopathology (2018) 29:407–17.  10.1111/cyt.12575
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cyt.12575</ArticleId>
            <ArticleId IdType="pubmed">29768677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yi K-I, Ahn S, Park DY, Lee J-C, Lee B-J, Wang S-G, et al. . False-positive Cytopathology Results for Papillary Thyroid Carcinoma: A Trap for Thyroid Surgeons. Clin Otolaryngol (2017) 42:1153–60.  10.1111/coa.12840
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/coa.12840</ArticleId>
            <ArticleId IdType="pubmed">28130940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Canberk S, Firat P, Schmitt F. Pitfalls in the Cytological Assessment of Thyroid Nodules. Turk Patoloji Derg (2015) 31:18–33.  10.5146/tjpath.2015.01312
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5146/tjpath.2015.01312</ArticleId>
            <ArticleId IdType="pubmed">26177315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Harvey AM, Truong LD, Mody DR. Diagnostic Pitfalls of Hashimoto’s/Lymphocytic Thyroiditis on Fine-Needle Aspirations and Strategies to Avoid Overdiagnosis. Acta Cytol (2012) 56:352–60.  10.1159/000338738
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000338738</ArticleId>
            <ArticleId IdType="pubmed">22846513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ravinsky E, Safneck JR. Differentiation of Hashimoto’s Thyroiditis From Thyroid Neoplasms in Fine Needle Aspirates. Acta Cytol (1988) 32:854–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3201876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Elliott DD, Pitman MB, Bloom L, Faquin WC. FNA Biopsy of Hürthle Cell Lesions of the Thyroid Gland: A Cytomorphologic Study of 139 Cases With Statistical Analysis. Cancer (2006) 108:102–9.  10.1002/cncr.21716
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.21716</ArticleId>
            <ArticleId IdType="pubmed">16453320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kasper KA, Stewart J, Das K. Fine-Needle Aspiration Cytology of Thyroid Nodules With Hürthle Cells: Cytomorphologic Predictors for Neoplasms, Improving Diagnostic Accuracy and Overcoming Pitfalls. Acta Cytol (2014) 58:145–52.  10.1159/000358264
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000358264</ArticleId>
            <ArticleId IdType="pubmed">24525356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Alaedeen DI, Khiyami A, McHenry CR. Fine-Needle Aspiration Biopsy Specimen With a Predominance of Hürthle Cells: A Dilemma in the Management of Nodular Thyroid Disease. Surgery (2005) 138:650–7.  10.1016/j.surg.2005.06.047
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.surg.2005.06.047</ArticleId>
            <ArticleId IdType="pubmed">16269293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Auger M. Hürthle Cells in Fine-Needle Aspirates of the Thyroid. A Review of Their Diagnostic Criteria and Significance. Cancer Cytopathol (2014) 122:241–9.  10.1002/cncy.21391
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncy.21391</ArticleId>
            <ArticleId IdType="pubmed">24436122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Faquin WC, Cibas ES, Renshaw A. “Atypical” Cells in Fine-Needle Aspiration Biopsy Specimens of Benign Thyroid Cysts. Cancer (2005) 105:71–9.  10.1002/cncr.20832
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.20832</ArticleId>
            <ArticleId IdType="pubmed">15662703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yang GCH, Schreiner AM, Sun W. Can Abundant Colloid Exclude Oncocytic (Hürthle Cell) Carcinoma in Thyroid fine Needle Aspiration? Cytohistological Correlation of 127 Oncocytic (Hürthle Cell) Lesions. Cytopathology (2013) 24:185–93.  10.1111/j.1365-2303.2012.00988.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2303.2012.00988.x</ArticleId>
            <ArticleId IdType="pubmed">22672530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Renshaw A. Hürthle Cell Carcinoma is a Better Gold Standard Than Hürthle Cell Neoplasm for Fine-Needle Aspiration of the Thyroid: Defining More Consistent and Specific Cytologic Criteria. Cancer Cytopathol (2002) 96:261–6.  10.1002/cncr.10797
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.10797</ArticleId>
            <ArticleId IdType="pubmed">12378592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kini SR, Miller JM, Hamburger JI. Cytopathology of Hürthle Cell Lesions of the Thyroid Gland by fine Needle Aspiration. Acta Cytol (1981) 25:647–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6171979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yang YJ, Khurana KK. Diagnostic Utility of Intracytoplasmic Lumen and Transgressing Vessels in Evaluation of Hürthle Cell Lesions by Fine-Needle Aspiration. Arch Pathol Lab Med (2001) 125:1031–5.  10.1043/0003-9985(2001)125&lt;1031:DUOILA&gt;2.0.CO;2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1043/0003-9985(2001)125&lt;1031:DUOILA&gt;2.0.CO;2</ArticleId>
            <ArticleId IdType="pubmed">11473452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wu HH-J, Clouse J, Ren R. Fine-Needle Aspiration Cytology of Hürthle Cell Carcinoma of the Thyroid. Diagn Cytopathol (2008) 36:149–54.  10.1002/dc.2075067
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dc.2075067</ArticleId>
            <ArticleId IdType="pubmed">18232004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mu N, Juhlin CC, Tani E, Sofiadis A, Reihnér E, Zedenius J, et al. . High Ki-67 Index in Fine Needle Aspiration Cytology of Follicular Thyroid Tumors is Associated With Increased Risk of Carcinoma. Endocrine (2018) 61:293–302.  10.1007/s12020-018-1627-z
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-018-1627-z</ArticleId>
            <ArticleId IdType="pmc">PMC6061212</ArticleId>
            <ArticleId IdType="pubmed">29796987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Canberk S, Montezuma D, Ince U, Tastekin E, Soares P, Bongiovanni M, et al. . Variants of Papillary Thyroid Carcinoma: An Algorithmic Cytomorphology-Based Approach to Cytology Specimens. Acta Cytol (2020) 64:288–98.  10.1159/000503576
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000503576</ArticleId>
            <ArticleId IdType="pubmed">31634886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baloch Z, LiVolsi VA, Tondon R. Aggressive Variants of Follicular Cell Derived Thyroid Carcinoma; the So Called “Real Thyroid Carcinomas”. J Clin Pathol (2013) 66:733–43. 10.1136/jclinpath-2013-201626
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jclinpath-2013-201626</ArticleId>
            <ArticleId IdType="pubmed">23626010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Silver CE, Owen RP, Rodrigo JP, Rinaldo A, Devaney KO, Ferlito A. Aggressive Variants of Papillary Thyroid Carcinoma. Head Neck (2011) 33:1052–9. 10.1002/hed.21494
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hed.21494</ArticleId>
            <ArticleId IdType="pubmed">20824810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Asioli S, Maletta F, Pagni F, Pacchioni D, Vanzati A, Mariani S, et al. . Cytomorphologic and Molecular Features of Hobnail Variant of Papillary Thyroid Carcinoma: Case Series and Literature Review. Diagn Cytopathol (2014) 42:78–84.  10.1002/dc.23028
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dc.23028</ArticleId>
            <ArticleId IdType="pubmed">23913779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bellevicine C, Cozzolino I, Malapelle U, Zeppa P, Troncone G. Cytological and Molecular Features of Papillary Thyroid Carcinoma With Prominent Hobnail Features: A Case Report. Acta Cytol. (2012) 56(5):560–4. 10.1159/000338395
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000338395</ArticleId>
            <ArticleId IdType="pubmed">23075900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wenter V, Jellinek A, Unterrainer M, Ahmaddy F, Lehner S, Albert NL, et al. . Long-Term Outcome of Rare Oncocytic Papillary (Hürthle Cell) Thyroid Carcinoma Following (Adjuvant) Initial Radioiodine Therapy. Eur J Nucl Med Mol Imaging (2019) 46:2526–35.  10.1007/s00259-019-04456-8
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00259-019-04456-8</ArticleId>
            <ArticleId IdType="pubmed">31410542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Carr AA, Yen TWF, Ortiz DI, Hunt BC, Fareau G, Massey BL, et al. . Patients With Oncocytic Variant Papillary Thyroid Carcinoma Have a Similar Prognosis to Matched Classical Papillary Thyroid Carcinoma Controls. Thyroid (2018) 28:1462–7.  10.1089/thy.2017.0603
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2017.0603</ArticleId>
            <ArticleId IdType="pubmed">30215297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Baloch ZW, LiVolsi VA. Warthin-Like Papillary Carcinoma of the Thyroid. Arch Pathol Lab Med (2000) 124:1192–5.  10.1043/0003-9985(2000)124&lt;1192:WLPCOT&gt;2.0.CO;2
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1043/0003-9985(2000)124&lt;1192:WLPCOT&gt;2.0.CO;2</ArticleId>
            <ArticleId IdType="pubmed">10923082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lastra RR, LiVolsi VA, Baloch ZW. Aggressive Variants of Follicular Cell-Derived Thyroid Carcinomas: A Cytopathologist’s Perspective. Cancer. Cytopathol (2014) 122:484–503.  10.1002/cncy.21417
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncy.21417</ArticleId>
            <ArticleId IdType="pubmed">24664970</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Solomon A, Gupta PK, LiVolsi VA, Baloch ZW. Distinguishing Tall Cell Variant of Papillary Thyroid Carcinoma From Usual Variant of Papillary Thyroid Carcinoma in Cytologic Specimens. Diagn Cytopathol (2002) 27:143–8. 10.1002/dc.10156
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dc.10156</ArticleId>
            <ArticleId IdType="pubmed">12203860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Das DK, Mallik MK, Sharma P, Sheikh ZA, Mathew PA, Sheikh M, et al. . Papillary Thyroid Carcinoma and its Variants in Fine Needle Aspiration Smears. A Cytomorphologic Study With Special Reference to Tall Cell Variant. Acta Cytol (2004) 48:325–36.  10.1159/000326381
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000326381</ArticleId>
            <ArticleId IdType="pubmed">15192947</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW. Does Hurthle Cell Lesion/Neoplasm Predict Malignancy More Than Follicular Lesion/Neoplasm on Thyroid Fine-Needle Aspiration? Diagn Cytopathol (2006) 34:330–4.  10.1002/dc.20440
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dc.20440</ArticleId>
            <ArticleId IdType="pubmed">16604553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Giorgadze T, Rossi ED, Fadda G, Gupta PK, Livolsi VA, Baloch Z. Does the Fine-Needle Aspiration Diagnosis of “Hürthle-Cell Neoplasm/Follicular Neoplasm With Oncocytic Features” Denote Increased Risk of Malignancy? Diagn Cytopathol (2004) 31:307–12.  10.1002/dc.20132
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dc.20132</ArticleId>
            <ArticleId IdType="pubmed">15468114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Roh MH, Jo VY, Stelow EB, Faquin WC, Zou KH, Alexander EK, et al. . The Predictive Value of the Fine-Needle Aspiration Diagnosis “Suspicious for a Follicular Neoplasm, Hurthle Cell Type” in Patients With Hashimoto Thyroiditis. Am J Clin Pathol (2011) 135:139–45.  10.1309/AJCP0RW2WMDUAKGK
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1309/AJCP0RW2WMDUAKGK</ArticleId>
            <ArticleId IdType="pubmed">21173136</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mai KT, Elmontaser G, Perkins DG, Thomas J, Stinson WA. Benign Hürthle Cell Adenoma With Papillary Architecture: A Benign Lesion Mimicking Oncocytic Papillary Carcinoma. Int J Surg Pathol (2005) 13:37– 41.  10.1177/106689690501300105
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/106689690501300105</ArticleId>
            <ArticleId IdType="pubmed">15735853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Woodford RL, Nikiforov YE, Hunt JL, Bellizzi AM, Zhang X. Mills SE, et al. Encapsulated Papillary Oncocytic Neoplasms of the Thyroid: Morphologic, Immunohistochemical, and Molecular Analysis of 18 Cases. Am J Surg Pathol (2010) 34:1582–90.  10.1097/PAS.0b013e3181f2d820
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAS.0b013e3181f2d820</ArticleId>
            <ArticleId IdType="pubmed">20924280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bellevicine C, Malapelle U, Docimo G, Ciancia G, Mossetti G, Pettinato G, et al. . Multicentric Encapsulated Papillary Oncocytic Neoplasm of the Thyroid: A Case Diagnosed by a Combined Cytological, Histological, Immunohistochemical, and Molecular Approach. Diagn Cytopathol (2012) 40:450–4.  10.1002/dc.21828
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dc.21828</ArticleId>
            <ArticleId IdType="pubmed">21965084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Apel RL, Asa SL, LiVolsi VA. Papillary Hürthle Cell Carcinoma With Lymphocytic Stroma. “Warthin-Like Tumor” of the Thyroid. Am J Surg Pathol (1995) 19:810–4. 10.1097/00000478-199507000-00009
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00000478-199507000-00009</ArticleId>
            <ArticleId IdType="pubmed">7793479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kim J, Lim BJ, Hong SW, Pyo JY. Preoperative Cytologic Diagnosis of Warthin-Like Variant of Papillary Thyroid Carcinoma. J Pathol Transl Med (2018) 52:105–9.  10.4132/jptm.2017.12.26
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4132/jptm.2017.12.26</ArticleId>
            <ArticleId IdType="pmc">PMC5859244</ArticleId>
            <ArticleId IdType="pubmed">29429327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dettmer M, Schmitt A, Steinert H, Moch H, Komminoth P, Perren A. Poorly Differentiated Oncocytic Thyroid Carcinoma—Diagnostic Implications and Outcome. Histopathology (2012) 60:1045–51.  10.1111/j.1365-2559.2012.04188.x53
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2559.2012.04188.x53</ArticleId>
            <ArticleId IdType="pubmed">22348590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Asioli S, Erickson LA, Righi A, Jin L, Volante M, Jenkins S, et al. . Poorly Differentiated Carcinoma of the Thyroid: Validation of the Turin Proposal and Analysis of IMP3 Expression. Mod Pathol (2010) 23:1269–78.  10.1038/modpathol.2010.117
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/modpathol.2010.117</ArticleId>
            <ArticleId IdType="pubmed">20562850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wong KS, Lorch JH, Alexander EK, Marqusee E, Cho NL, Nehs MA, et al. . Prognostic Significance of Extent of Invasion in Poorly Differentiated Thyroid Carcinoma. Thyroid (2019) 29:1255–61.  10.1089/thy.2019.0263
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2019.0263</ArticleId>
            <ArticleId IdType="pubmed">31397224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bongiovanni M, Bloom L, Krane JF, Baloch ZW, Powers CN, Hintermann S, et al. . Cytomorphologic Features of Poorly Differentiated Thyroid Carcinoma: A Multi-Institutional Analysis of 40 Cases. Cancer Cytopathol (2009) 117:185–94.  10.1002/cncy.20023
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncy.20023</ArticleId>
            <ArticleId IdType="pubmed">19365842</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kane SV, Sharma TP. Cytologic Diagnostic Approach to Poorly Differentiated Thyroid Carcinoma: A Single-Institution Study. Cancer Cytopathol (2015) 123:82–91.  10.1002/cncy.21500
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncy.21500</ArticleId>
            <ArticleId IdType="pubmed">25557073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Onenerk M, Canberk S, Gunes P, Erkan M, Kilicoglu GZ. Oncocytic Variant of Poorly Differentiated Thyroid Carcinoma: “Is Diagnosis Possible by Fine-Needle Aspiration?”
Cytojournal (2016) 13:23.  10.4103/1742-6413.192188
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/1742-6413.192188</ArticleId>
            <ArticleId IdType="pmc">PMC5070041</ArticleId>
            <ArticleId IdType="pubmed">27761148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Laforga JB, Cortés VA. Oncocytic Poorly Differentiated (Insular) Thyroid Carcinoma Mimicking Metastatic Adenocarcinoma. A Case Report and Review of the Literature. Diagn Cytopathol (2019) 47:584–8.  10.1002/dc.24147
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dc.24147</ArticleId>
            <ArticleId IdType="pubmed">30637975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Papaparaskeva K, Nagel H, Droese M. Cytologic Diagnosis of Medullary Carcinoma of the Thyroid Gland. Diagn Cytopathol (2000) 22:351–8.  10.1002/(sici)1097-0339(200006)22:6&lt;351::aid-dc5&gt;3.0.co;2-t
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/(sici)1097-0339(200006)22:6&lt;351::aid-dc5&gt;3.0.co;2-t</ArticleId>
            <ArticleId IdType="pubmed">10820528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Trimboli P, Treglia G, Guidobaldi L, Romanelli F, Nigri G, Valabrega S, et al. . Detection Rate of FNA Cytology in Medullary Thyroid Carcinoma: A Meta-Analysis. Clin Endocrinol (2015) 82:280–5.  10.1111/cen.12563
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cen.12563</ArticleId>
            <ArticleId IdType="pubmed">25047365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Canberk S, Onenerk M, Gunes P, Sayman E, Kilicoglu G. Oncocytic Variant of Medullary Thyroid Carcinoma. Endocr Pathol (2015) 26:320–3.  10.1007/s12022-015-9389-0
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-015-9389-0</ArticleId>
            <ArticleId IdType="pubmed">26293669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Spaulding SL, Ho R, Everest S, Chai RL. The Role of Molecular Testing in the Diagnosis of Medullary Thyroid Cancer: A Case Report of Oncocytic Medullary Thyroid Carcinoma and Review of the Literature. Am J Otolaryngol (2020) 41:102312.  10.1016/j.amjoto.2019.102312
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amjoto.2019.102312</ArticleId>
            <ArticleId IdType="pubmed">31727331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dedivitis RA, Di Giovanni JH, Silva GF, Marinho LC, Guimarães AV. Oncocytic Variant Ofmedullary Thyroid Carcinoma: Case Report. Arq Bras Endocrinol Metabol (2004) 48:315–7.  10.1590/s0004-27302004000200017
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1590/s0004-27302004000200017</ArticleId>
            <ArticleId IdType="pubmed">15640889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kaushal S, Iyer VK, Mathur SR, Ray R. Fine Needle Aspiration Cytology of Medullary Carcinoma of the Thyroid With a Focus on Rare Variants: A Review of 78 Cases. Cytopathology (2011) 22:95–105.  10.1111/j.1365-2303.2010.00747.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2303.2010.00747.x</ArticleId>
            <ArticleId IdType="pubmed">20518799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sams SB, Tompkins KD, Mayson S, Raeburn CD, Mehrotra S. Oncocytic Variant of Medullary Thyroid Carcinoma; A Rare Tumor With Numerous Diagnostic Mimics by Fine Needle Aspiration. Diagn Cytopathol (2017) 45:1148–52.  10.1002/dc.23790
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dc.23790</ArticleId>
            <ArticleId IdType="pubmed">28802094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maximo V, Sobrinho-Simoes M. Hürthle Cell Tumours of the Thyroid. A Review With Emphasis on Mitochondrial Abnormalities With Clinical Relevance. Virchows Arch (2000) 437:107–15.  10.1007/s004280000219
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s004280000219</ArticleId>
            <ArticleId IdType="pubmed">10993269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maximo V, Sobrinho-Simoes M. Mitochondrial DNA ‘Common’ Deletion in Hürthle Cell Lesions of the Thyroid. J Pathol (2000) 192:561–2.  10.1002/1096-9896(200012)192:4&lt;561::AID-PATH790&gt;3.0.CO;2-3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1096-9896(200012)192:4&lt;561::AID-PATH790&gt;3.0.CO;2-3</ArticleId>
            <ArticleId IdType="pubmed">11113879</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ganly I, McFadden DG. Short Review: Genomic Alterations in Hürthle Cell Carcinoma. Thyroid (2019) 29:471–9.  10.1089/thy.2019.0088
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2019.0088</ArticleId>
            <ArticleId IdType="pubmed">30848171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ganly I, Makarov V, Deraje S, Dong Y, Reznik E, Seshan V, et al. . Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell (2018) 34:256–70.  10.1016/j.ccell.2018.07.002
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2018.07.002</ArticleId>
            <ArticleId IdType="pmc">PMC6247912</ArticleId>
            <ArticleId IdType="pubmed">30107176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn GW, Tallini G, et al. . RAS Point Mutations and PAX8-PPAR Gamma Rearrangement in Thyroid Tumors: Evidence for Distinct Molecular Pathways in Thyroid Follicular Carcinoma. J Clin Endocrinol Metab (2003) 88:2318–26.  10.1210/jc.2002-021907
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2002-021907</ArticleId>
            <ArticleId IdType="pubmed">12727991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, et al. . TERT Promoter Mutations are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas. J Clin Endocrinol Metab (2014) 99:E754–765.  10.1210/jc.2013-3734
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2013-3734</ArticleId>
            <ArticleId IdType="pmc">PMC4191548</ArticleId>
            <ArticleId IdType="pubmed">24476079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chindris AM, Casler JD, Bernet VJ, Rivera M, Thomas C, Kachergus JM, et al. . Clinical and Molecular Features of Hürthle Cell Carcinoma of the Thyroid. J ClinEndocrinol Metab (2015) 100:55–62.  10.1210/jc.2014-1634
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2014-1634</ArticleId>
            <ArticleId IdType="pubmed">25259908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vinagre J, Almeida A, Pópulo H, Batista R, Lyra J, Pinto V, et al. . Frequency of TERT Pro- Moter Mutations in Human Cancers. Nat Commun (2013) 4:2185.  10.1038/ncomms3185
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms3185</ArticleId>
            <ArticleId IdType="pubmed">23887589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, et al. . Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease. J Clin Endocrinol Metab (2013) 98:E1562–1566.  10.1210/jc.2013-2383
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2013-2383</ArticleId>
            <ArticleId IdType="pmc">PMC3763971</ArticleId>
            <ArticleId IdType="pubmed">23833040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
de Vries MM, Celestino R, Castro P, Eloy C, Máximo V, Van Der Wal JE, et al. . RET/PTC Rearrangement is Prevalent in Follicular Hürthle Cell Carcinomas. Histopathology (2012) 61:833–43.  10.1111/j.1365-2559.2012.04276.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2559.2012.04276.x</ArticleId>
            <ArticleId IdType="pubmed">22803838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cheung CC, Ezzat S, Ramyar L, Freeman JL, Asa SL. Molecular Basis Off Hürthle Cell Papillary Thyroid Carcinoma. J Clin Endocrinol Metab (2000) 85:878–82.  10.1210/jcem.85.2.6404
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jcem.85.2.6404</ArticleId>
            <ArticleId IdType="pubmed">10690905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chiappetta G, Toti P, Cetta F, Giuliano A, Pentimalli F, Amendola I, et al. . The RET/PTC Oncogene is Frequently Activated in Oncocytic Thyroid Tumors (Hürthle Cell Adenomas and Carcinomas), But Not in Oncocytic Hyperplastic Lesions. J Clin Endocrinol Metab (2002) 87:364–49.  10.1210/jcem.87.1.8180
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jcem.87.1.8180</ArticleId>
            <ArticleId IdType="pubmed">11788677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gopal RK, Kübler K, Calvo SE, Polak P, Livitz D, Rosebrocket D, et al. . Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma. Cancer Cell (2018) 34:242–355.  10.1016/j.ccell.2018.06.013
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2018.06.013</ArticleId>
            <ArticleId IdType="pmc">PMC6121811</ArticleId>
            <ArticleId IdType="pubmed">30107175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ganly I, Ricarte Filho J, Eng S, Ghossein R, Morris LG, Liang Y, et al. . Genomic Dissection of Hürthle Cell Carcinoma Reveals a Unique Class of Thyroid Malignancy. J Clin Endocrinol Metab (2013) 98:E962–972.  10.1210/jc.2012-3539
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2012-3539</ArticleId>
            <ArticleId IdType="pmc">PMC5393465</ArticleId>
            <ArticleId IdType="pubmed">23543667</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Corver WE, Ruano D, Weijers K, den Hartog WC, van Nieuwenhuizen MP, de Miranda N, et al. . Genome Haploidisation With Chromosome 7 Retention in Oncocytic Follicular Thyroid Carcinoma. PloS One (2012) . 7:e38287.  10.1371/journal.pone.0038287
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0038287</ArticleId>
            <ArticleId IdType="pmc">PMC3365880</ArticleId>
            <ArticleId IdType="pubmed">22675538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Corver WE, van Wezel T, Molenaar K, Schrumpf M, van den Akker B, van Eijk R, et al. . Near-haploidization Significantly Associates With Oncocytic Adrenocortical, Thyroid, and Parathyroid Tumors But Not With Mitochondrial DNA Mutations. Genes Chromosomes Cancer (2014) 53:833–44.  10.1002/gcc.22194
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/gcc.22194</ArticleId>
            <ArticleId IdType="pubmed">24909752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nikiforova MN, Tseng GC, Steward D, Diorio D, Nikiforov YE. MicroRNA Expression Profiling of Thyroid Tumors: Biological Significance and Diagnostic Utility. J Clin Endocrinol Metab (2008) 93:1600–8. 10.1210/jc.2007-2696
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2007-2696</ArticleId>
            <ArticleId IdType="pmc">PMC2386678</ArticleId>
            <ArticleId IdType="pubmed">18270258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Brauner E, Holmes BJ, Krane JF, Nishino M, Zurakowski D, Hennessey JV, et al. . Performance of the Afirma Gene Expression Classifier in Hürthle Cell Thyroid Nodules Differs From Other Indeterminate Thyroid Nodules. Thyroid (2015) 25:789–96.  10.1089/thy.2015.0049
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2015.0049</ArticleId>
            <ArticleId IdType="pubmed">25962906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lastra RR, Pramick MR, Crammer CJ, LiVolsi VA, Baloch ZW. Implications of a Suspicious Afirma Test Result in Thyroid Fine-Needle Aspiration Cytology: An Institutional Experience. Cancer Cytopathol (2014) 122:737–44.  10.1002/cncy.21455
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncy.21455</ArticleId>
            <ArticleId IdType="pubmed">25123499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Yang SE, Sullivan PS, Zhang J, Govind R, Levin MR, Rao JY, et al. . Has Afirma Gene Expression Classifier Testing Refined the Indeterminate Thyroid Category in Cytology? Cancer Cytopathol (2016) 124:100–9.  10.1002/cncy.21624
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncy.21624</ArticleId>
            <ArticleId IdType="pubmed">26422098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
McIver B, Castro MR, Morris JC, Bernet V, Smallridge R, Henry M, et al. . An Independent Study of a Gene Expression Classifier (Afirma) in the Evaluation of Cytologically Indeterminate Thyroid Nodules. J Clin Endocrinol Metab (2014) 99:4069–77.  10.1210/jc.2013-3584
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2013-3584</ArticleId>
            <ArticleId IdType="pubmed">24780044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, et al. . Preoperative Diagnosis of Benign Thyroid Nodules With Indeterminate Cytology. N Engl J Med (2012) 367:705–15.  10.1056/NEJMoa1203208
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1203208</ArticleId>
            <ArticleId IdType="pubmed">22731672</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Harrell RM, Bimston DN. Surgical Utility of Afirma: Effects of High Cancer Prevalence and Oncocytic Cell Types in Patients With Indeterminate Thyroid Cytology. Endocr Pract (2014) 20:364–9.  10.4158/EP13330.OR
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4158/EP13330.OR</ArticleId>
            <ArticleId IdType="pubmed">24246351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wu JX, Young S, Hung ML, Li N, Yang SE, Cheung DS, et al. . Clinical Factors Influencing the Performance of Gene Expression Classifier Testing in Indeterminate Thyroid Nodules. Thyroid (2016) 26:916–22.  10.1089/thy.2015.0505
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2015.0505</ArticleId>
            <ArticleId IdType="pubmed">27161519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Patel KN, Angell TE, Babiarz J, Barth NM, Blevins T, Duh QY, et al. . Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules. JAMA Surg (2018) 153:817–24.  10.1001/jamasurg.2018.1153
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamasurg.2018.1153</ArticleId>
            <ArticleId IdType="pmc">PMC6583881</ArticleId>
            <ArticleId IdType="pubmed">29799911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
San Martin VT, Lawrence L, Bena J, Madhun NZ,  Berber E, Elsheikh TM, et al. . Real-World Comparison of Afirma GEC and GSC for the Assessment of Cytologically Indeterminate Thyroid Nodules. J Clin Endocrinol Metab (2020) 105:428–35.  10.1210/clinem/dgz099
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/clinem/dgz099</ArticleId>
            <ArticleId IdType="pubmed">31665322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Pearlstein S, Lahouti AH, Opher E, Nikiforov YE, Kuriloff DB. Thyroseq V3 Molecular Profiling for Tailoring the Surgical Management of Hürthle Cell Neoplasms. Case Rep Endocrinol (2018) 2018:9329035.  10.1155/2018/9329035
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2018/9329035</ArticleId>
            <ArticleId IdType="pmc">PMC6076910</ArticleId>
            <ArticleId IdType="pubmed">30105107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ahmadi S, Stang M, Jiang XS, Sosa JA. ḦRthle Cell Carcinoma: Current Perspectives. Onco Targets Ther (2016) 9:6873–84.  10.2147/OTT.S119980
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S119980</ArticleId>
            <ArticleId IdType="pmc">PMC5106236</ArticleId>
            <ArticleId IdType="pubmed">27853381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hassan A, Khalid M, Riaz S, Nawaz MK, Bashir H. Follicular Thyroid Carcinoma: Disease Response Evaluation Using American Thyroid Association Risk Assessment Guidelines. Eur Thyroid J (2015) 4:260–65.  10.1159/000442237
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000442237</ArticleId>
            <ArticleId IdType="pmc">PMC4716413</ArticleId>
            <ArticleId IdType="pubmed">26835430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
National Comprehensive Cancer Network . Thyroid Cancer (Version 1.2018) . Available at: https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf (Accessed November 8, 2018).</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
